Brief: Lumibird Medical's Glaucoma Treatment Potential Strengthened By EGS Recommendations
13/04/2021 16:52
April 13 (Reuters) - Lumibird SA LBIRD.PA :
* REG-LUMIBIRD MEDICAL’S GLAUCOMA TREATMENT POTENTIAL
FURTHER
STRENGTHENED BY THE LATEST EGS RECOMMENDATIONS
Source text for Eikon: ID:nGNEbfmJ9G
Further company coverage: LBIRD.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Lumibird SA
See all newsBrief: Lumibird - H1 Net Income Up +4.5% To EUR 5.1 Million
Brief: Lumibird Signs A Share Purchase Agreement For The Sale Of Lumibird Medical To IPG Photonics Corporation
Brief: Lumibird H1 Revenue Up +9.7% Lfl to €114.7 Mln
Brief: Lumibird Signs Agreement With Cilas
Brief: Lumibird Enters Into Exclusive Negotiations For The Sale Of Its Medical Division To IPG Photonics Corporation